The Latin America, Middle East and Africa Gastrointestinal Therapeutics Market would witness market growth of 9.6% CAGR during the forecast period (2022-2028).
Structural gastrointestinal disease is when one’s bowel looks abnormal during the examination and doesn’t function properly. In some cases, the structural abnormality is required to be removed surgically. Structural GI diseases include strictures, hemorrhoids, inflammatory bowel disease, colon cancer, colon polyps, and stenosis.
Constipation, a functional problem, makes it hard for the patient to have a bowel movement (or pass stools). As a result, the stools are infrequent (less than three times a week) or incomplete. Constipation is generally caused by an inadequate “roughage” or fiber in one’s diet or disruption in their routine. Constipation usually doesn’t mean any serious medical condition.
Irritable bowel syndrome (also called spastic colon, IBS, nervous stomach or irritable colon) is a functional condition where the patients colon muscle contracts more or less often than “normal”. Certain foods, medicines and emotional stress are some factors which are known to triggers IBS. Hemorrhoids are expanded veins in the anal canal, which cause a structural disease.
Dubai spent around AED 19.49 billion on healthcare which was 5.3 % of their GDP, the annual growth rate was just 1% after accounting for change in the utilization pattern because of the COVID-19 pandemic. The spending on ancillary services and medical goods was 13% and 15% respectively. The spending on perspective care services were lower than 1% and the government allocated 23% of their health expenditure to administration and governance functions. The private insurance spent 36% of their total health expenditure on ancillary services and medical goods.
The Brazil market dominated the LAMEA Gastrointestinal Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,032.1 million by 2028. The Argentina market is estimated to grow a CAGR of 10.2% during (2022 - 2028). Additionally, The UAE market would experience a CAGR of 9.3% during (2022 - 2028).
Based on Type, the market is segmented into Branded and Generics. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on Route of Administration, the market is segmented into Injectable and Oral & Others. Based on Application, the market is segmented into Crohn's Disease, Ulcerative Colitis, GERD, IBS and Others. Based on Drug Class, the market is segmented into Biologics/Biosimilar, Anti-Diarrheal, Anti-Emetics, Digestive Enzymes, Aminosalicylates, Proton Pump Inhibitors, Laxatives & H2 Antagonists and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Gastrointestinal Therapeutics Market is Predict to reach $45.9 Billion by 2028, at a CAGR of 3.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, AbbVie, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc., Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.), Johnson & Johnson (Janssen Global Services, LLC), AstraZeneca PLC, Bayer AG, Sun Pharmaceutical Industries Ltd., and Cipla Limited.
By Type
By Distribution Channel
By Route of Administration
By Application
By Drug Class
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
